Navigation Links
Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting

t treatment with these or other agents associated with myopathy should weigh carefully the potential benefits and risks and should monitor and advise patients to report any signs or symptoms of unexplained muscle pain, tenderness or weakness, particularly during periods of upward dosage titration. TYZEKA therapy should be interrupted if myopathy is suspected, and discontinued if myopathy is diagnosed. -- Because TYZEKA is eliminated primarily by renal excretion, co- administration of TYZEKA with drugs that affect renal function may alter plasma concentrations of TYZEKA and/or the coadministered drug. Dose interval adjustment is required in patients with creatinine clearance <50mL/min including those with end stage renal disease on hemodialysis. For patients on hemodialysis, telbivudine should be administered after hemodialysis. -- The safety and efficacy of TYZEKA in liver transplant recipients are unknown. If TYZEKA treatment is determined to be necessary for a liver transplant recipient who has received or is receiving an immunosuppressant that may affect renal function, such as cyclosporine or tacrolimus, renal function should be monitored both before and during treatment with TYZEKA. -- Patients should be advised that treatment with TYZEKA has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination. -- Safety and effectiveness of TYZEKA in pediatric patients under the age of 16 years have not been established. -- Most common adverse events (>5%) in clinical studies, regardless of attributability to telbivudine, were upper respiratory tract infection (14%), fatigue and malaise (12%), abdominal pain (12%), nasopharyngitis (11%), headache (11%), blood CPK increased (9%), cough (7%), nausea and vo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Inferior Vena Cava (IVC) Filters - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... projected to reach US$435 million by 2016. The ... (2015) of the global value while Europe ...
(Date:12/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... added to the NASDAQ Biotechnology Index (NBI). The ... effective upon market open on December 22, 2014. ... to track the performance of a set of ... or pharmaceutical according to the Industry Classification Benchmark. ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Schizophrenia is one of the most disabling diseases,(1) ... of the disease place enormous burdens on patients, ... the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... reduce rates of rehospitalization among patients with schizophrenia. ...
... Calif., May 19 Apieron, Inc. ( www.apieron.com ... the appointment of Steve Bubrick as Vice President, Sales ... Both appointments are effective immediately. Mr. Bubrick has more ... the consumer medical device industry, mainly in diabetes management. ...
... Encision Inc. (OTC Bulletin Board: ECIA), a medical ... as a standard of care in minimally-invasive surgery, reported ... year ended March 31, 2009.Net sales for the fourth ... totaled $3.1 million, representing a 3% decrease over net ...
... STOCKHOLDERSADVOCAT BOARD NEEDS TO EXPLORE THE SALE OR MERGER ... Fund, Ltd. ("Bristol") announced today that it has sent ... "Company") (Nasdaq: AVCA ) urging stockholders to ... Paul Kessler and Richard McKilligan, at the Company,s 2009 ...
... athlete,s foot sufferers and parents.KENILWORTH, N.J., May 19 ... SGP ) today announced the arrival ... treatment of athlete,s foot. TINACTIN CHILL is available ... spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )To view the ...
... Mark Best Programs in Sustainable Healthcare CHICAGO, ... only membership association devoted to environmentally responsible ... Award winners. These competitive awards are ... for outstanding programs to reduce the facility,s ...
Cached Medicine News:Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 2Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 3Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 4Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 5Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 6Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 7Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 8Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 9Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 10Health News:Apieron Strengthens Senior Leadership With Commercial, Financial Appointments 2Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 3Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 4Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 5Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 6Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 7Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 8
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: